Literature DB >> 28546707

Clinico-pathological Study of Limb Salvage Surgery for Osteosarcoma: Experience in a Rural Cancer Center.

Divya Vijayanarasimha1, Sangeetha K Nayanar1, Syam Vikram2, Vijay M Patil3, Satheesh Babu4.   

Abstract

Although recent multimodality therapeutic protocols have led to improved survival in osteosarcoma (OS), the outcome still remains dismal. Ongoing international multicentric trials on OS aim to randomize patients for optimum management, based on histological response to NACT. The pathologic response to neoadjuvant chemotherapy (NACT) is the most important factor predicting prognosis. In this study of 23 cases of limb salvage surgery post neoadjuvant chemotherapy, mean age was 18.3 years, with male predominance. 65.5 % cases were conventional OS. Histologic assessment of chemotherapeutic effect done by Huvos grading revealed good response (Huvos lll and lV) in 15 (65.2 %) and poor response (Huvos l and ll) in eight (34.8 %). A scoring based on MRI with a scale of 1-6 was compared with histologic response. Five (62.5 %) of poor responders showed score of >3 and 73.3 % of good responders showed ≤3. Dose intensity of NACT was calculated and correlated with the histological response. 53.3 % of good responders showed ARDI > 0.9. Five (21.7 %) developed local recurrence and 10(43.4 %) had pulmonary metastasis. Adoption of more aggressive treatment modalities may ensure better histologic response and longer event free survival.

Entities:  

Keywords:  Histological response osteosarcoma; Huvos scoring system; Limb salvage surgery; Neoadjuvant chemotherapy; Osteosarcoma; Radiological scoring osteosarcoma

Year:  2016        PMID: 28546707      PMCID: PMC5427016          DOI: 10.1007/s13193-016-0547-8

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  21 in total

1.  Comparison of long-term outcome between doublet and triplet neoadjuvant chemotherapy in non-metastatic osteosarcoma of the extremity.

Authors:  Soojung Hong; Sang Joon Shin; Minkyu Jung; Jaeheon Jeong; Young Joo Lee; Kyoo-Ho Shin; Jae Kyung Roh; Sun Young Rha
Journal:  Oncology       Date:  2011-06-14       Impact factor: 2.935

Review 2.  Osteosarcoma multidisciplinary approach to the management from the pathologist's perspective.

Authors:  A Kevin Raymond; Norman Jaffe
Journal:  Cancer Treat Res       Date:  2009

Review 3.  Treatment effects in pediatric soft tissue and bone tumors: practical considerations for the pathologist.

Authors:  Cheryl M Coffin; Amy Lowichik; Holly Zhou
Journal:  Am J Clin Pathol       Date:  2005-01       Impact factor: 2.493

4.  Tumor necrosis in pediatric osteosarcoma: impact of modern therapies.

Authors:  Eleanor Hendershot; Alberto Pappo; David Malkin; Lillian Sung
Journal:  J Pediatr Oncol Nurs       Date:  2006 Jul-Aug       Impact factor: 1.636

5.  Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement.

Authors:  A G Huvos; G Rosen; R C Marcove
Journal:  Arch Pathol Lab Med       Date:  1977-01       Impact factor: 5.534

6.  Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide.

Authors:  G Bacci; A Briccoli; M Rocca; S Ferrari; D Donati; A Longhi; F Bertoni; P Bacchini; S Giacomini; C Forni; M Manfrini; S Galletti
Journal:  Ann Oncol       Date:  2003-07       Impact factor: 32.976

7.  Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651.

Authors:  Allen M Goorin; Douglas J Schwartzentruber; Meenakshi Devidas; Mark C Gebhardt; Alberto G Ayala; Michael B Harris; Lee J Helman; Holcombe E Grier; Michael P Link
Journal:  J Clin Oncol       Date:  2003-04-15       Impact factor: 44.544

Review 8.  Malignant bone tumors: limb sparing versus amputation.

Authors:  Matthew R DiCaprio; Gary E Friedlaender
Journal:  J Am Acad Orthop Surg       Date:  2003 Jan-Feb       Impact factor: 3.020

Review 9.  Prognostic factors in osteosarcoma: a critical review.

Authors:  A M Davis; R S Bell; P J Goodwin
Journal:  J Clin Oncol       Date:  1994-02       Impact factor: 44.544

10.  Prognostic value of histological response to chemotherapy in osteosarcoma patients receiving tumor-bearing frozen autograft.

Authors:  Shinji Miwa; Akihiko Takeuchi; Hiroko Ikeda; Toshiharu Shirai; Norio Yamamoto; Hideji Nishida; Katsuhiro Hayashi; Yoshikazu Tanzawa; Hiroaki Kimura; Kentaro Igarashi; Hiroyuki Tsuchiya
Journal:  PLoS One       Date:  2013-08-15       Impact factor: 3.240

View more
  4 in total

1.  CircPRDM2 Contributes to Doxorubicin Resistance of Osteosarcoma by Elevating EZH2 via Sponging miR-760.

Authors:  Jianjun Yuan; Yan Liu; Quan Zhang; Zhishuai Ren; Guang Li; Rong Tian
Journal:  Cancer Manag Res       Date:  2021-06-02       Impact factor: 3.989

2.  Rutin attenuates Sorafenib-induced Chemoresistance and Autophagy in Hepatocellular Carcinoma by regulating BANCR/miRNA-590-5P/OLR1 Axis.

Authors:  Meng Zhou; Gan Zhang; Jun Hu; Yanzhi Zhu; Haoming Lan; Xianfeng Shen; Yi Lv; Linsheng Huang
Journal:  Int J Biol Sci       Date:  2021-08-19       Impact factor: 6.580

Review 3.  Origin and Therapies of Osteosarcoma.

Authors:  Brice Moukengue; Morgane Lallier; Louise Marchandet; Marc Baud'huin; Franck Verrecchia; Benjamin Ory; Francois Lamoureux
Journal:  Cancers (Basel)       Date:  2022-07-19       Impact factor: 6.575

4.  Effect of Different Anesthesia Methods on Emergence Agitation and Related Complications in Postoperative Patients with Osteosarcoma.

Authors:  Minghuan Zhang; Bo Wang; Wen Mao
Journal:  J Healthc Eng       Date:  2021-12-14       Impact factor: 2.682

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.